Detalles de la búsqueda
1.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Blood;
141(14): 1675-1684, 2023 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36542826
2.
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.
Blood;
140(4): 349-358, 2022 07 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35316325
3.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet;
399(10343): 2294-2308, 2022 06 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35717989
4.
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Blood;
137(19): 2646-2656, 2021 05 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512419
5.
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.
Ann Hematol;
102(10): 2791-2801, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37552322
6.
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Am J Hematol;
97(8): 1023-1034, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35617104
7.
Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group).
Ann Hematol;
100(4): 1031-1038, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33242101
8.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Lancet;
394(10216): 2271-2281, 2019 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31868632
9.
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
Br J Haematol;
184(5): 760-768, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30520013
10.
The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.
Ann Hematol;
98(7): 1755-1763, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30993417
11.
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Future Oncol;
: 1-11, 2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38547003
12.
Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation.
Blood;
128(26): 3169-3176, 2016 12 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-27811019
13.
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
Biol Blood Marrow Transplant;
23(1): 44-52, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27720995
14.
The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.
Blood;
124(5): 720-8, 2014 Jul 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-24939657
15.
Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.
Haematologica;
101(6): 773-80, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26969081
16.
High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis.
Blood;
122(18): 3220-9, 2013 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-24046013
17.
Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.
Lancet Oncol;
15(7): 757-66, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24827808
18.
Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Transplant Cell Ther;
30(6): 584.e1-584.e13, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38281590
19.
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial.
Leukemia;
38(5): 1099-1106, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38538861
20.
Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor.
Bone Marrow Transplant;
59(5): 597-603, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38331980